MML Investors Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.9M | Sell |
33,419
-4,585
| -12% | -$2.14M | 0.04% | 421 |
|
|
2025
Q4 | $17.2M | Buy |
38,004
+3,773
| +11% | +$1.63M | 0.04% | 396 |
|
|
2025
Q3 | $13.4M | Sell |
34,231
-2,376
| -6% | -$993K | 0.04% | 454 |
|
|
2025
Q2 | $16.3M | Sell |
36,607
-4,448
| -11% | -$2.05M | 0.05% | 381 |
|
|
2025
Q1 | $19.9M | Buy |
41,055
+4,836
| +13% | +$2.25M | 0.07% | 297 |
|
|
2024
Q4 | $14.6M | Sell |
36,219
-11,858
| -25% | -$5.5M | 0.05% | 352 |
|
|
2024
Q3 | $22.4M | Buy |
48,077
+10,437
| +28% | +$5.01M | 0.08% | 245 |
|
|
2024
Q2 | $17.6M | Sell |
37,640
-3,875
| -9% | -$1.68M | 0.07% | 270 |
|
|
2024
Q1 | $17.4M | Buy |
41,515
+2,338
| +6% | +$988K | 0.07% | 276 |
|
|
2023
Q4 | $15.9M | Buy |
39,177
+6,186
| +19% | +$2.29M | 0.07% | 265 |
|
|
2023
Q3 | $11.5M | Buy |
32,991
+8,059
| +32% | +$2.82M | 0.06% | 302 |
|
|
2023
Q2 | $8.77M | Buy |
24,932
+4,229
| +20% | +$1.42M | 0.05% | 355 |
|
|
2023
Q1 | $6.52M | Sell |
20,703
-3,113
| -13% | -$934K | 0.05% | 374 |
|
|
2022
Q4 | $6.88M | Buy |
23,816
+2,441
| +11% | +$744K | 0.05% | 397 |
|
|
2022
Q3 | $6.19M | Buy |
21,375
+400
| +2% | +$115K | 0.05% | 388 |
|
|
2022
Q2 | $5.91M | Buy |
20,975
+2,280
| +12% | +$610K | 0.04% | 376 |
|
|
2022
Q1 | $4.88M | Buy |
18,695
+5,833
| +45% | +$1.38M | 0.03% | 455 |
|
|
2021
Q4 | $2.82M | Buy |
12,862
+1,729
| +16% | +$336K | 0.02% | 619 |
|
|
2021
Q3 | $2.02M | Buy |
11,133
+143
| +1% | +$27.9K | 0.02% | 722 |
|
|
2021
Q2 | $2.22M | Sell |
10,990
-6,282
| -36% | -$1.31M | 0.02% | 673 |
|
|
2021
Q1 | $3.71M | Buy |
17,272
+1,381
| +9% | +$303K | 0.04% | 437 |
|
|
2020
Q4 | $3.76M | Buy |
15,891
+2,603
| +20% | +$597K | 0.04% | 385 |
|
|
2020
Q3 | $3.62M | Sell |
13,288
-374
| -3% | -$103K | 0.05% | 345 |
|
|
2020
Q2 | $3.97M | Buy |
13,662
+6,947
| +103% | +$1.88M | 0.05% | 307 |
|
|
2020
Q1 | $1.6M | Buy |
6,715
+1,352
| +25% | +$310K | 0.03% | 479 |
|
|
2019
Q4 | $1.17M | Buy |
5,363
+1,170
| +28% | +$237K | 0.02% | 662 |
|
|
2019
Q3 | $710K | Sell |
4,193
-689
| -14% | -$122K | 0.01% | 817 |
|
|
2019
Q2 | $895K | Buy |
4,882
+852
| +21% | +$149K | 0.01% | 757 |
|
|
2019
Q1 | $741K | Buy |
4,030
+469
| +13% | +$86.6K | 0.01% | 830 |
|
|
2018
Q4 | $590K | Sell |
3,561
-206
| -5% | -$35.7K | 0.01% | 829 |
|
|
2018
Q3 | $726K | Buy |
3,767
+1,179
| +46% | +$210K | 0.01% | 811 |
|
|
2018
Q2 | $440K | Buy |
2,588
+288
| +13% | +$44.6K | 0.01% | 903 |
|
|
2018
Q1 | $375K | Sell |
2,300
-109
| -5% | -$17.8K | 0.01% | 970 |
|
|
2017
Q4 | $361K | Sell |
2,409
-1,664
| -41% | -$246K | 0.01% | 1003 |
|
|
2017
Q3 | $619K | Buy |
4,073
+2,185
| +116% | +$329K | 0.01% | 697 |
|
|
2017
Q2 | $243K | Sell |
1,888
-53
| -3% | -$6.38K | ﹤0.01% | 1091 |
|
|
2017
Q1 | $212K | Buy |
+1,941
| New | +$171K | ﹤0.01% | 718 |
|
Other funds holding VRTX
VCM
VPM
MML Investors Services's VRTX Position: Q1 2026 in Review
MML Investors Services reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, selling an estimated $2.14M and leaving 33,419 shares worth $14.9M. The position accounts for 0.04% of the portfolio, ranked #421.
MML Investors Services first reported a position in VRTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $22.4M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- MML Investors Services held 33,419 shares of Vertex Pharmaceuticals worth $14.9M as of Q1 2026.
- MML Investors Services sold 4,585 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.14M.
- Vertex Pharmaceuticals made up 0.04% of MML Investors Services's portfolio in Q1 2026, its #421 holding.
- MML Investors Services first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- MML Investors Services's Vertex Pharmaceuticals position peaked at $22.4M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.